Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Auerswald

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Thrombosis and Haemostasis|January 23, 1992
Prevention of hepatitis C virus infection in children with haemophilia A and B and von Willebrand's diseaseW Kreuz, G Auerswald, C Brückmann, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 24, 2016
Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-upW Kreuz, S Ehrenforth, M Funk, et al.
The New England Journal of Medicine|April 9, 1987
Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusionsK Schimpf, P M Mannucci, W Kreutz, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 8, 2013
Novel coagulation factor concentrates: issues relating to their clinical implementation and pharmacokinetic assessment for optimal prophylaxis in haemophilia patientsR Ljung, G Auerswald, G Benson, et al.
The New England Journal of Medicine|October 26, 1989
Absence of anti-human immunodeficiency virus types 1 and 2 seroconversion after the treatment of hemophilia A or von Willebrand's disease with pasteurized factor VIII concentrateK Schimpf, H H Brackmann, W Kreuz, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 11, 2004
Continuous infusion of B-domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experienceN Stieltjes, C Altisent, G Auerswald, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 11, 2007
Evaluation of pharmacokinetics, efficacy and safety of Immunate solvent detergent in previously treated patients with severe haemophilia AL Nemes, T Lissitchkov, A Klukowska, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 28, 2004
Health status and health-related quality of life of children with haemophilia from six West European countriesA Gringeri, S von Mackensen, G Auerswald, et al.
Acta Haematologica|February 29, 2008
Pharmacokinetics, efficacy and safety of IMMUNATE solvent/detergent (IMMUNATE S/D) in previously treated patients with severe hemophilia A: results of a prospective, multicenter, open-label phase III studyL Nemes, T Lissitchkov, G Dobaczewski, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 21, 2007
Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia CentresM Morfini, G Auerswald, R A Kobelt, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Thrombosis and Haemostasis|January 23, 1992
Prevention of hepatitis C virus infection in children with haemophilia A and B and von Willebrand's diseaseW Kreuz, G Auerswald, C Brückmann, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 24, 2016
Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-upW Kreuz, S Ehrenforth, M Funk, et al.
The New England Journal of Medicine|April 9, 1987
Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusionsK Schimpf, P M Mannucci, W Kreutz, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 8, 2013
Novel coagulation factor concentrates: issues relating to their clinical implementation and pharmacokinetic assessment for optimal prophylaxis in haemophilia patientsR Ljung, G Auerswald, G Benson, et al.
The New England Journal of Medicine|October 26, 1989
Absence of anti-human immunodeficiency virus types 1 and 2 seroconversion after the treatment of hemophilia A or von Willebrand's disease with pasteurized factor VIII concentrateK Schimpf, H H Brackmann, W Kreuz, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 11, 2004
Continuous infusion of B-domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experienceN Stieltjes, C Altisent, G Auerswald, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 11, 2007
Evaluation of pharmacokinetics, efficacy and safety of Immunate solvent detergent in previously treated patients with severe haemophilia AL Nemes, T Lissitchkov, A Klukowska, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 28, 2004
Health status and health-related quality of life of children with haemophilia from six West European countriesA Gringeri, S von Mackensen, G Auerswald, et al.
Acta Haematologica|February 29, 2008
Pharmacokinetics, efficacy and safety of IMMUNATE solvent/detergent (IMMUNATE S/D) in previously treated patients with severe hemophilia A: results of a prospective, multicenter, open-label phase III studyL Nemes, T Lissitchkov, G Dobaczewski, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 21, 2007
Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia CentresM Morfini, G Auerswald, R A Kobelt, et al.
Pageof 5